HCPCS Code Descriptor:
Ciltacabtagene autoleucel, up to 100 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
Route of Administration:
CARVYKTI is an Oncology drug manufactured by Janssen and administered via the Intravenous route of administration. The Q Code: Q2056 is aligned to the drug CARVYKTI.